News

Video

Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis

Author(s):

Mazyar Shadman, MD, MPH

This is an evaluation of the results of a network meta-analysis covering the comparative efficacy of bruton tyrosine kinase Inhibitors in relapse/refractory chronic lymphocytic leukemia.

Related Videos
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
Reid Merryman, MD
Partow Kebriaei, MD
Jean L. Koff, MD, MS
Sonali M. Smith, MD
Naval G. Daver, MD,
A panel of 5 experts on CLL
A panel of 5 experts on CLL
Andrew Hantel, MD
Related Content
William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Leonard Mazur, CEO, Citius Pharma, Citius Oncology
September 6th 2024

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Reid W. Merryman, MD
September 5th 2024

Novel Cell-Free DNA Assays Expand the Reach of MRD Detection in Lymphoma

Rayne Helen Rouce, MD, BS, Baylor College of Medicine
September 4th 2024

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL